RT Journal Article
SR Electronic
T1 Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.11.24309649
DO 10.1101/2024.07.11.24309649
A1 Sundar, Shyam
A1 Alves, Fabiana
A1 Ritmeijer, Koert
A1 den Boer, Margriet
A1 Forsyth, Colin
A1 Hughes, Bethan
A1 Zamble, Clare
A1 Carter, Kirsten
A1 Angyalosi, Gerhild
YR 2024
UL http://medrxiv.org/content/early/2024/07/11/2024.07.11.24309649.abstract
AB Background Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in India. VL primarily affects rural, low-income populations with limited health care access. In South Asia, few studies have explored patients’ perspectives, diagnoses, and treatment experiences, and how these experiences influence their expectations about treatment.Methodology/principal findings A qualitative study was conducted in Bihar, India, using moderator-facilitated, protocol-defined discussion. Eighteen adult patients and 12 caregivers of children diagnosed with and treated for VL within the last 12 months were identified by self-report. Mean time from symptom onset to diagnosis was 13.8 days. Challenges of the patient life experience included lack of urgency by health care professionals, delayed diagnosis, and unavailability of current standard-of-care therapy where a patient receives their diagnosis (63% switched to a different center for treatment, at times delaying treatment). Key barriers include out-of-pocket financial burden, absence from work/home duties, and long-distance travel to hospitals. Patients expressed a preference (29/30) for a potential oral treatment that could be taken close to home over the current standard of care (infusions/injections in clinics).Conclusions/significance This study reveals new insights and confirms previous research showing access to care for patients with VL in the Bihar area remains a challenge. Although most patients with VL seek care early, diagnosis often requires multiple visits to a health care facility. Despite access to therapy in public hospitals, a substantial number of patients prefer private clinics. Even in public locations, many patients need to move from the diagnostic center to another center to receive therapy, creating an additional burden for patients. As a potential alternative to current parenteral treatment, oral therapy would be preferred by adult patients and caregivers of pediatric patients and may reduce barriers to access to care.AUTHOR SUMMARY This is an interview-based investigation of patient awareness, experience, and individual challenges for adults and caregivers of children seeking diagnosis and effective care for visceral leishmaniasis (VL) in rural districts of Bihar, India. Patients’ descriptions of their health experiences revealed obstacles at every stage, including limited information about the illness at the community level, financial burdens associated with loss of work, and cost of travel to seek diagnosis. Although our study was subject to recall bias, it elicited insights from the patients’ own experiences and revealed deterrents and burdens that may not have been visible otherwise. Our study also found that most patients would prefer a potential oral treatment for VL over the current parenteral–based standard of care. This patient-driven approach of identifying unmet needs and potential gaps in public health access can be useful in furthering the aims of the National Elimination Program for VL in India and in other areas with endemic VL, particularly those planning to introduce elimination programs.Competing Interest StatementS. Sundar has received consulting fees from Novartis Pharma AG. F. Alves and C. Forsyth are employed by Drugs for Neglected Diseases initiative (nonprofit organization). K. Ritmeijer and M. den Boer have no conflicts of interest to disclose. B. Hughes is employed by Novartis Pharmaceuticals UK Ltd and received stock options from Novartis Pharma AG. C. Zambles company (Lumanity) has been contracted and paid by Novartis Pharma AG for writing support and market research. K. Carter and G. Angyalosi are employees of Novartis Pharma AG and received stock options from Novartis Pharma AG.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (IRB) ethics approval was received from Sigma-IRB (https://www.sigma-irb.com/) on December 28, 2022.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesStudy data are available in Supporting Information 1.